Tyme Technologies, Inc., a clinical-stage biotechnology company, develops novel cancer therapeutics. It is developing SM-88, a combination therapy based on dysfunctional metyrosine derivatives in Phase II development for metastatic pancreatic cancer and biomarker-recurrent prostate cancer. The company was founded in 2011 and is headquartered in New York, New York.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TYME
CUSIPN/A
Phone212-461-2315
Debt
Debt-to-Equity RatioN/A
Current Ratio7.87
Quick Ratio7.87
Price-To-Earnings
Trailing P/E Ratio-11.10
Forward P/E Ratio-7.28
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.27 per share
Price / Book8.63
Profitability
EPS (Most Recent Fiscal Year)($0.21)
Net Income$-18,960,000.00
Net MarginsN/A
Return on Equity-144.70%
Return on Assets-117.96%
Miscellaneous
EmployeesN/A
Outstanding Shares101,230,000
Market Cap$240.92 million
Tyme Technologies (NASDAQ:TYME) Frequently Asked Questions
What is Tyme Technologies' stock symbol?
Tyme Technologies trades on the NASDAQ under the ticker symbol "TYME."
When is Tyme Technologies' next earnings date?
What price target have analysts set for TYME?
3 brokers have issued twelve-month price targets for Tyme Technologies' stock. Their forecasts range from $7.00 to $10.00. On average, they expect Tyme Technologies' share price to reach $8.8333 in the next year. This suggests a possible upside of 279.1% from the stock's current price. View Analyst Price Targets for Tyme Technologies.
What is the consensus analysts' recommendation for Tyme Technologies?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tyme Technologies in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Tyme Technologies.
What are Wall Street analysts saying about Tyme Technologies stock?
Here are some recent quotes from research analysts about Tyme Technologies stock:
- 1. According to Zacks Investment Research, "Tyme Technologies, Inc. is a pharmaceutical company. The company is focused on creating medicines which specialize in the body's immune system to treat diseases. Tyme Technologies, Inc. is headquartered in New York. " (10/12/2018)
- 2. HC Wainwright analysts commented, "We maintain our Buy rating of TYME and our 12-month price target of $9.50 per share. We derive our price target based on a net present value analysis of projected SM-88 revenues through FY2030 assuming a 12% discount rate and 2% terminal growth rate. We derive an rNPV of $1.3B for SM-88 and include $22M in net cash to arrive at a 12-month price target of $9.46 per diluted share, which we round to $9.50. (1) clinical; (2) regulatory; (3) commercial; (4) financial; and (5) intellectual property." (10/11/2018)
- 3. Canaccord Genuity analysts commented, "We continue to view SM-88’s ability to generate responses across ~15 solid and liquid tumor types and with durable effect in advanced cancer patients progressing on available therapies as intriguing and reiterate our BUY rating." (6/15/2018)
Who are some of Tyme Technologies' key competitors?
Some companies that are related to Tyme Technologies include Zai Lab (ZLAB), Rhythm Pharmaceuticals (RYTM), Lexicon Pharmaceuticals (LXRX), Revance Therapeutics (RVNC), Akorn (AKRX), Eagle Pharmaceuticals (EGRX), Aptinyx (APTX), Athenex (ATNX), Radius Health (RDUS), Alder Biopharmaceuticals (ALDR), Amphastar Pharmaceuticals (AMPH), Viking Therapeutics (VKTX), Deciphera Pharmaceuticals (DCPH), MacroGenics (MGNX) and AMAG Pharmaceuticals (AMAG).
Who are Tyme Technologies' key executives?
Tyme Technologies' management team includes the folowing people:
- Mr. Steven E. Hoffman, Co-Founder, Chairman, CEO & Chief Science Officer (Age 55)
- Mr. Ben R. Taylor, Pres & CFO (Age 41)
- Mr. Michael S. Demurjian, Exec. VP, COO & Director (Age 51)
- Dr. Jonathan M. Eckard, Chief Scientific Affairs Officer (Age 44)
- Mr. James Biehl J.D., Chief Legal Officer, Sec. & Director (Age 54)
How do I buy shares of Tyme Technologies?
Shares of TYME can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Tyme Technologies' stock price today?
One share of TYME stock can currently be purchased for approximately $2.33.
How big of a company is Tyme Technologies?
Tyme Technologies has a market capitalization of $240.92 million. The company earns $-18,960,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis.
What is Tyme Technologies' official website?
How can I contact Tyme Technologies?
Tyme Technologies' mailing address is 17 STATE STREET 7TH FLOOR, NEW YORK NY, 10004. The company can be reached via phone at 212-461-2315 or via email at [email protected]
MarketBeat Community Rating for Tyme Technologies (NASDAQ TYME)
MarketBeat's community ratings are surveys of what our community members think about Tyme Technologies and other stocks. Vote "Outperform" if you believe TYME will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TYME will underperform the S&P 500 over the long term. You may vote once every thirty days.
